打开APP

百时美施贵宝及辉瑞Eliquis获FDA批准

  1. Eliquis
  2. 百时美施贵宝
  3. 辉瑞
  4. 阿哌沙班

来源:生物谷 2012-12-29 09:32

2012年12月28日 讯 /生物谷BIOON/ --百时美施贵宝(BMS)及辉瑞(Pfizer)宣布,Eliquis(apixaban,阿哌沙班)获美国FDA和日本监管部门批准,用于非瓣膜性房颤(NVAF)患者缺血性中风及全身性栓塞的预防。这是6周内继欧盟、加拿大之后获得的最新监管批准。

2012年12月28日 讯 /生物谷BIOON/ --百时美施贵宝(BMS)及辉瑞(Pfizer)宣布,Eliquis(apixaban,阿哌沙班)获美国FDA和日本监管部门批准,用于非瓣膜性房颤(NVAF)患者缺血性中风及全身性栓塞的预防。这是6周内继欧盟、加拿大之后获得的最新监管批准。(生物谷bioon.com)

英文原文1:

Bristol-Myers Squibb (NYSE: BMY : 32.05, -0.09) and Pfizer Inc. (NYSE: PFE : 25.06, -0.07) said ELIQUIS (apixaban) for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) has been approved by Japan health regulators.

The approval in Japan marks the third regulatory approval for ELIQUIS within six weeks, following approvals in the European Union and Canada, the companies noted.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-Myers Squibb.

According to the companies, ELIQUIS is a novel anticoagulant that has demonstrated risk reductions versus warfarin in three important outcomes of stroke, major bleeding and all-cause death. ELIQUIS is an oral direct Factor Xa inhibitor, part of a novel therapeutic class.

Atrial fibrillation is the most common cardiac arrhythmia, a condition of irregular heart beat, which is responsible for roughly 20 percent of all strokes in Japan.

The companies said the approval of ELIQUIS in Japan is supported by the pivotal Phase 3 trial, ARISTOTLE, which evaluated the safety and efficacy of ELIQUIS versus warfarin in 18,201 patients with NVAF, including 336 patients from Japan.

In addition, the safety and efficacy of ELIQUIS in Japanese patients were evaluated in a subanalysis of the ARISTOTLE study, which demonstrated results consistent with the overall study.

The U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date is March 17, 2013.

BMY shares closed at $32.46 on Monday, while PFE shares ended at $25.08.

英文原文2:http://www.reuters.com/article/2012/12/28/us-fda-eliquis-idUSBRE8BR0JT20121228


 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->